Gastrointestinal stromal tumors, version 2.2014: Featured updates to the NCCN Guidelines

  • Margaret Von Mehren
  • , R. Lor Randall
  • , Robert S. Benjamin
  • , Sarah Boles
  • , Marilyn M. Bui
  • , Ephraim S. Casper
  • , Ernest U. Conrad
  • , Thomas F. DeLaney
  • , Kristen N. Ganjoo
  • , Suzanne George
  • , Ricardo J. Gonzalez
  • , Martin J. Heslin
  • , John M. Kane
  • , Joel Mayerson
  • , Sean V. McGarry
  • , Christian Meyer
  • , Richard J. O'Donnell
  • , Alberto S. Pappo
  • , I. Benjamin Paz
  • , John D. Pfeifer
  • Richard F. Riedel, Scott Schuetze, Karen D. Schupak, Herbert S. Schwartz, Brian A. Van Tine, Jeffrey D. Wayne, Mary Anne Bergman, Hema Sundar

Research output: Contribution to journalArticlepeer-review

106 Scopus citations

Abstract

Gastrointestinal stromal tumors (GIST) are the most common soft tissue sarcoma of the gastrointestinal tract, resulting most commonly from KIT or platelet-derived growth factor receptor α (PDGFRα)-activating mutations. These NCCN Guideline Insights high-light the important updates to the NCCN Guidelines for Soft Tissue Sarcoma specific to the management of patients with GIST experiencing disease progression while on imatinib and/or sunitinib.

Original languageEnglish
Pages (from-to)853-862
Number of pages10
JournalJournal of the National Comprehensive Cancer Network : JNCCN
Volume12
Issue number6
DOIs
StatePublished - Jun 1 2014

Fingerprint

Dive into the research topics of 'Gastrointestinal stromal tumors, version 2.2014: Featured updates to the NCCN Guidelines'. Together they form a unique fingerprint.

Cite this